TG Therapeutics to Join Jefferies Global Healthcare Conference on June 5, 2024

TG Therapeutics, Inc. (NASDAQ: TGTX) has announced that Michael S. Weiss, the company’s Chairman and CEO, will be participating in the Jefferies Global Healthcare Conference. This event is set to take place at the Marriott Marquis in New York City from June 5 to June 6, 2024. Mr. Weiss’s fireside chat is scheduled for Wednesday, June 5, 2024, at 1:30 PM ET. Interested parties can view a live webcast of this discussion on the Events page within the Investors & Media section of TG Therapeutics' website.

About TG Therapeutics

TG Therapeutics is a biopharmaceutical company that has fully integrated its commercial operations. The company's main focus is the acquisition, development, and commercialization of innovative treatments aimed at B-cell diseases. Their research pipeline includes several investigational drugs, and they have achieved significant regulatory milestones.

The U.S. Food and Drug Administration (FDA) has approved BRIUMVI® (ublituximab-xiiy) for treating adult patients with various forms of relapsing multiple sclerosis (RMS). This includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. Additionally, the European Commission (EC) and the Medicines and Healthcare Products Regulatory Agency (MHRA) have approved BRIUMVI for treating adult patients with RMS in Europe and the United Kingdom, respectively. These approvals are based on the drug's efficacy for patients with active disease defined by clinical or imaging features.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!